[go: up one dir, main page]

MX2019008413A - Celulas pluripotentes inmunodiseñadas. - Google Patents

Celulas pluripotentes inmunodiseñadas.

Info

Publication number
MX2019008413A
MX2019008413A MX2019008413A MX2019008413A MX2019008413A MX 2019008413 A MX2019008413 A MX 2019008413A MX 2019008413 A MX2019008413 A MX 2019008413A MX 2019008413 A MX2019008413 A MX 2019008413A MX 2019008413 A MX2019008413 A MX 2019008413A
Authority
MX
Mexico
Prior art keywords
pluripotent cells
avoid
provides
immunoengineered
rejection
Prior art date
Application number
MX2019008413A
Other languages
English (en)
Inventor
SCHREPFER Sonja
Deuse Tobias
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2019008413A publication Critical patent/MX2019008413A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/005—Vectors comprising a special translation-regulating system cell cycle specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01021—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona células pluripotentes que se usan terapéuticamente para regenerar tejidos que evitan el rechazo de los sujetos que las reciben. En particular, la invención proporciona células pluripotentes hipoinmunogénicas que evitan el rechazo inmune del huésped. Las células carecen de antígenos inmunes importantes que desencadenan respuestas inmunes y están diseñadas para evitar la endocitosis fagocítica. La invención proporciona además células pluripotentes "disponibles en el mercado" universalmente aceptables y derivados de las mismas para generar o regenerar tejidos y órganos específicos.
MX2019008413A 2017-01-13 2018-01-14 Celulas pluripotentes inmunodiseñadas. MX2019008413A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762445969P 2017-01-13 2017-01-13
PCT/US2018/013688 WO2018132783A1 (en) 2017-01-13 2018-01-14 Immunoengineered pluripotent cells

Publications (1)

Publication Number Publication Date
MX2019008413A true MX2019008413A (es) 2019-09-13

Family

ID=61148505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008413A MX2019008413A (es) 2017-01-13 2018-01-14 Celulas pluripotentes inmunodiseñadas.

Country Status (12)

Country Link
US (2) US20190376045A1 (es)
EP (1) EP3568464A1 (es)
JP (3) JP2020505025A (es)
KR (2) KR20190103373A (es)
CN (1) CN110177869A (es)
AU (2) AU2018207649B2 (es)
BR (1) BR112019014257A2 (es)
CA (1) CA3049766A1 (es)
EA (1) EA201991692A1 (es)
IL (1) IL267616A (es)
MX (1) MX2019008413A (es)
WO (1) WO2018132783A1 (es)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9888673B2 (en) 2014-12-10 2018-02-13 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
AU2016362129A1 (en) 2015-12-04 2018-06-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
KR20190103373A (ko) * 2017-01-13 2019-09-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포
AU2018239320B2 (en) * 2017-03-20 2024-10-31 Washington University Cells and methods of uses and making the same
SG11201907434RA (en) 2017-03-22 2019-10-30 Novartis Ag Compositions and methods for immunooncology
GB2588249B (en) 2017-06-12 2023-01-04 Sinai Health Sys Allograft tolerance without the need for systemic immune suppression
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
KR20210032454A (ko) * 2018-07-17 2021-03-24 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능성 세포로부터의 분화 세포
CN112639081A (zh) * 2018-07-17 2021-04-09 加利福尼亚大学董事会 从免疫工程化多能干细胞衍生的嵌合抗原受体t细胞
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
CN113195724A (zh) * 2018-09-26 2021-07-30 新加坡国立大学 低免疫原性的工程化人类间充质基质细胞，制备方法和试剂盒
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
CN111424016A (zh) * 2019-01-09 2020-07-17 复旦大学 降低细胞免疫原性的诱导型多能干细胞系及建立方法
BR112021016178A2 (pt) * 2019-02-15 2021-11-03 Harvard College Células-tronco doadoras universais e métodos relacionados
CN113811362A (zh) * 2019-05-10 2021-12-17 加利福尼亚大学董事会 修饰的多能细胞
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
EP3990627A4 (en) 2019-06-26 2023-07-19 The Regents of The University of California SIRP-ALPHA SILENCED NATURAL KILLER CELLS (NK)
TW202115245A (zh) * 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
EP4022037A1 (en) 2019-07-10 2022-07-06 Helmuth Heinrich Kunz Methods for deriving autologous and hypoimmunogenic hair follicle containing sheets in vitro
WO2021022223A1 (en) 2019-08-01 2021-02-04 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
JP7728747B2 (ja) 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
EP4025690A1 (en) 2019-09-05 2022-07-13 CRISPR Therapeutics AG Universal donor cells
BR112022004031A2 (pt) 2019-09-05 2022-08-16 Crispr Therapeutics Ag Células doadoras universais
CA3153700A1 (en) * 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
WO2021055985A1 (en) * 2019-09-22 2021-03-25 Cellerant Therapeutics, Inc. Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
AU2020365937A1 (en) * 2019-10-15 2022-04-28 The Regents Of The University Of California Transplanted cell protection via Fc sequestration
JP2023510872A (ja) * 2020-01-13 2023-03-15 サナ バイオテクノロジー，インコーポレイテッド 血液型抗原の修飾
EP4090349A4 (en) * 2020-01-15 2024-06-05 The Regents of The University of California TRANSPLANTED CELL PROTECTION BY INHIBITING POLYMORPHENUCULAR CELLS
WO2021146627A1 (en) 2020-01-17 2021-07-22 Sana Biotechnology, Inc. Safety switches for regulation of gene expression
BR112022019060A2 (pt) * 2020-03-25 2022-11-29 Sana Biotechnology Inc Células neurais hipoimunogênicas para o tratamento de distúrbios e condições neurológicas
WO2021207121A1 (en) * 2020-04-06 2021-10-14 Rxcell Inc. Hypoimmunogenic cells and methods and compositions for their production
AU2021259612A1 (en) * 2020-04-21 2022-11-10 Intima Bioscience, Inc. Cellular vaccine platform and methods of use
WO2021231712A1 (en) * 2020-05-15 2021-11-18 Rxcell Inc. Hypoimmunogenic cells and uses thereof in immune responses
US20220049226A1 (en) 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
CN112342196A (zh) * 2020-08-18 2021-02-09 未来智人再生医学研究院(广州)有限公司 一种免疫兼容可逆的通用型多能干细胞及其应用
WO2022076928A1 (en) * 2020-10-09 2022-04-14 Sana Biotechnology, Inc. METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPα BLOCKADE AGENT
CA3196346A1 (en) * 2020-10-20 2022-04-28 Herman Waldmann Methods and compositions for cellular therapy
CN114525255A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达il-11的多能干细胞衍生物及其应用
CN114457021A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd47抗体的多能干细胞及其衍生物与应用
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
CA3201621A1 (en) 2020-12-03 2022-06-09 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN114107211B (zh) * 2020-12-04 2025-09-30 未来智人再生医学研究院(广州)有限公司 一种多能干细胞及其衍生物
JP2023552441A (ja) * 2020-12-07 2023-12-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＳＩＲＰ－αエンゲージャーによる自然免疫細胞のサイレンシング
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
IL303473A (en) 2020-12-31 2023-08-01 Sana Biotechnology Inc Methods and compositions for modulating car-t activity
US11578309B2 (en) 2020-12-31 2023-02-14 Crispr Therapeutics Ag Universal donor cells
US20220296572A1 (en) 2021-03-03 2022-09-22 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
JPWO2022191216A1 (es) * 2021-03-09 2022-09-15
WO2022212393A1 (en) * 2021-03-30 2022-10-06 The Regents Of The University Of California Transplanted cell protection via modified fc receptors
JP2024520462A (ja) * 2021-05-24 2024-05-24 サンガモ セラピューティクス，インコーポレイテッド ジンクフィンガーヌクレアーゼを標的としたｃｉｉｔａ
CA3216346A1 (en) 2021-05-27 2022-12-01 Edward Rebar Hypoimmunogenic cells comprising engineered hla-e or hla-g
CA3225283A1 (en) 2021-07-14 2023-01-19 Sonja SCHREPFER Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
KR102847814B1 (ko) * 2021-07-28 2025-08-21 의료법인 성광의료재단 B2m 유전자의 발현이 저해된 유전적으로 조작된 줄기세포 및 이의 이용방법
EP4384193A2 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
US20240425820A1 (en) 2021-08-11 2024-12-26 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
CA3227613A1 (en) 2021-08-11 2023-02-16 William Dowdle Inducible systems for altering gene expression in hypoimmunogenic cells
AU2022325232A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
JP2024534772A (ja) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 同種異系細胞療法用の遺伝子改変細胞
CN117904109A (zh) * 2021-08-27 2024-04-19 浙江大学 一种超级增强子核心序列调控b2m基因表达的效果及应用
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
MX2024007528A (es) 2021-12-23 2024-08-30 Sana Biotechnology Inc Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados.
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
IL315000A (en) 2022-02-17 2024-10-01 Sana Biotechnology Inc Engineered cd47 proteins and uses thereof
US20250101382A1 (en) 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
CN114958768B (zh) * 2022-06-02 2023-03-24 健颐生物科技发展(山东)有限公司 Fgf10旁分泌通用型人成纤维细胞制剂的制备方法
CN117343962A (zh) * 2022-06-29 2024-01-05 中国科学院上海营养与健康研究所 免疫兼容型人多能干细胞、其制备方法及应用
MA71320A (fr) 2022-07-01 2025-04-30 Novo Nordisk A/S Amélioration de la différenciation neuronale de cellules progénitrices neurales du mésencéphale ventral
WO2024012420A1 (zh) * 2022-07-11 2024-01-18 士泽生物医药（苏州）有限公司 一种表达faslg的通用型细胞及其制备方法
CN117431217A (zh) * 2022-07-12 2024-01-23 上海驯鹿生物技术有限公司 表达靶向cd5的嵌合抗原受体(car)的细胞及其应用
GB202211117D0 (en) * 2022-07-29 2022-09-14 Replay Holdings Llc Compositions and methods for non-immunogenecity
GB202212144D0 (en) * 2022-08-19 2022-10-05 Resolution Therapeutics Ltd Cells for therapy
WO2024097315A2 (en) 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Cell therapy products and methods for producing same
EP4619015A1 (en) * 2022-11-15 2025-09-24 The Board of Trustees of the Leland Stanford Junior University Hypoallogenic-immunogenic pluripotent stem cells as anti-cancer vaccine
CN118147077B (zh) * 2022-12-07 2025-09-26 士泽生物医药（苏州）有限公司 一种表达gsn的通用型细胞及其制备方法
CN118207165A (zh) * 2022-12-07 2024-06-18 士泽生物医药（苏州）有限公司 一种表达stc1的通用型细胞及其制备方法
GB202218755D0 (en) * 2022-12-13 2023-01-25 Replay Holdings Llc Compositions and methods for non-immunogenicity
EP4636080A1 (en) * 2022-12-16 2025-10-22 Xellsmart Bio-Pharmaceutical (Suzhou) Co., Ltd. Universal cell and preparation method therefor
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024169917A1 (zh) * 2023-02-16 2024-08-22 士泽生物医药（苏州）有限公司 通用型细胞及其制备方法
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025003393A1 (en) 2023-06-30 2025-01-02 Novo Nordisk A/S Enhancing neuronal differentiation of neural progenitor cells
KR102740042B1 (ko) * 2023-07-12 2024-12-06 ㈜바이오솔빅스 인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
CN119351338A (zh) * 2023-09-15 2025-01-24 士泽生物医药（苏州）有限公司 一种表达cd300ld的低免疫原性细胞及其制备方法
WO2025096757A1 (en) 2023-11-01 2025-05-08 Sana Biotechnology, Inc. Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas
WO2025151838A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products
WO2025230947A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Engineered hepatocytes for secreting polypeptides
WO2025230941A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Hypoimmunogenic cell mixtures and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US20040053836A1 (en) * 2002-04-22 2004-03-18 Philipp Mayer-Kuckuk Method for modulating the production of a selected protein in vivo
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
EP2548950B1 (en) * 2009-06-05 2017-10-25 Cellular Dynamics International, Inc. Reprogramming T cells and hematopoietic cells
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
WO2013158292A1 (en) * 2012-04-17 2013-10-24 University Of Washington Through Its Center For Commercialization Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
CA2940460A1 (en) * 2014-03-07 2015-09-11 Bellicum Pharmaceuticals, Inc. Caspase polypeptides having modified activity and uses thereof
WO2015164740A1 (en) * 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
CN107683333A (zh) * 2015-03-11 2018-02-09 塞勒克提斯公司 用于工程化同种异体t细胞以增加其在患者中的持久性和/或移植成活率的方法
EP3294342A4 (en) * 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
ES2953925T3 (es) * 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes
KR20190103373A (ko) * 2017-01-13 2019-09-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포
CN113811362A (zh) * 2019-05-10 2021-12-17 加利福尼亚大学董事会 修饰的多能细胞

Also Published As

Publication number Publication date
AU2018207649A1 (en) 2019-07-11
IL267616A (en) 2019-08-29
BR112019014257A2 (pt) 2020-04-28
US20230348862A1 (en) 2023-11-02
KR20240095477A (ko) 2024-06-25
CN110177869A (zh) 2019-08-27
US20190376045A1 (en) 2019-12-12
EA201991692A1 (ru) 2019-12-30
AU2018207649B2 (en) 2024-08-01
WO2018132783A1 (en) 2018-07-19
JP2025069169A (ja) 2025-04-30
EP3568464A1 (en) 2019-11-20
CA3049766A1 (en) 2018-07-19
AU2024256086A1 (en) 2024-11-28
JP2023052079A (ja) 2023-04-11
KR20190103373A (ko) 2019-09-04
NZ754898A (en) 2023-11-24
JP2020505025A (ja) 2020-02-20

Similar Documents

Publication Publication Date Title
MX2019008413A (es) Celulas pluripotentes inmunodiseñadas.
MX2025004255A (es) Celulas diferenciadas de celulas pluripotentes inmunodise?adas
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
PH12017500803A1 (en) Anti-pd-1 antibodies
PH12019500193A1 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
PH12020500231A1 (en) Interleukin-21 muteins and methods of treatment
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
MX2019005127A (es) Poblaciones y productos de células madre mesenquimales y sus usos.
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
NZ737471A (en) Hydrophilic linkers for conjugation
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
MY188879A (en) Glycan therapeutics and related methods thereof
MY191944A (en) Binding proteins and methods of use thereof
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
EP4331622A3 (en) Integrin binding peptides and uses thereof
MX393281B (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
PH12018502139A1 (en) Phosphaplatin liquid formulations
PH12017501979A1 (en) Pharmaceutical compound
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.